Takashi Fukagai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Fukagai has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Hideki Yoshida
Department of Urology, Showa University School of Medicine, Tokyo, Japan
4 shared publications- Kazuhiko Oshinomi
Department of Urology Showa Medical University School of Medicine Tokyo Japan
4 shared publications - Masashi Morita
Department of Urology, Showa University Koto Toyosu Hospital, Tokyo, Japan
4 shared publications Atsushi Igarashi
Showa Univ, Dept Urol, Koto Toyosu Hosp, Tokyo, Japan
3 shared publications- Jun Morita
Department of Urology, Showa Medical University Hospital, Tokyo, Japan
3 shared publications Masakazu Nagata
Department of Urology Showa Medical University School of Medicine Tokyo Japan
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (6)
Refractory Retroperitoneal Abscess Caused by Hypermucoviscous Klebsiella pneumoniae Requiring Open Surgical Drainage
Introduction: Klebsiella pneumoniae is broadly classified into classical and hypervirulent pathotypes, with the latter associated with invasive infections and hematogenous dissemination. Case Presentation: An 89‐year‐old woman presented with fever and fatigue. Imaging revealed a large retroperitoneal abscess. Klebsiella pneumoniae was isolated from both pus and urine cultures, and the string test was positive. The clinical response to nonsurgical treatment was poor; however, definitive infection control was achieved after open surgical drainage. Conclusion: This case highlights serial reassessment and kidney‐preserving open drainage for string test‐positive infection refractory to percutaneous source control.
- 9 November 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (6)
Open AccessRefractory Retroperitoneal Abscess Caused by Hypermucoviscous Klebsiella pneumoniae Requiring Open Surgical Drainage
Introduction: Klebsiella pneumoniae is broadly classified into classical and hypervirulent pathotypes, with the latter associated with invasive infections and hematogenous dissemination. Case Presentation: An 89‐year‐old woman presented with fever and fatigue. Imaging revealed a large retroperitoneal abscess. Klebsiella pneumoniae was isolated from both pus and urine cultures, and the string test was positive. The clinical response to nonsurgical treatment was poor; however, definitive infection control was achieved after open surgical drainage. Conclusion: This case highlights serial reassessment and kidney‐preserving open drainage for string test‐positive infection refractory to percutaneous source control.
- 14 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8)
Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study
Background: Docetaxel (DTX) is commonly employed in patients with castration‐resistant prostate cancer (CRPC) following failure of androgen receptor signaling inhibitors (ARSIs). However, the impact of prior ARSI treatment on the efficacy of subsequent DTX therapy remains unclear. This study aimed to compare oncological outcomes between enzalutamide (ENZ)–DTX and abiraterone acetate plus prednisolone (ABI)–DTX sequential treatment strategies in patients with CRPC. Methods: The ENABLE study for PCa was an investigator‐initiated, multicenter, randomized controlled trial conducted in Japan to compare ENZ and ABI. This subanalysis evaluated the efficacy of subsequent DTX therapy in patients who had received either ENZ or ABI. Results: Between February 2015 and July 2019, 203 patients were enrolled, of whom 184 were randomized to receive ENZ or ABI (92 per arm). Among them, 20 and 21 patients subsequently initiated DTX therapy following ENZ and ABI, respectively. Median prostate cancer‐specific survival (PCSS) in the ENZ–DTX and ABI–DTX groups was 22.7 and 32.1 months, respectively ( p = 0.1724). Median PCSS from the initiation of DTX was 16.1 months in the ENZ–DTX group and 25.3 months in the ABI–DTX group ( p = 0.0966). In the overall cohort ( n = 41), patients who received additional ARSIs after ARSI–DTX therapy had significantly longer PCSS from the initiation of DTX compared with those who did not (median 21.6 vs. 13.8 months, p = 0.0157). Conclusions: ENZ–DTX and ABI–DTX sequential therapies demonstrated comparable survival outcomes in patients with CRPC. Notably, the administration of additional ARSIs following ARSI–DTX therapy may confer a survival benefit, suggesting a potential role for continued ARSI use in this treatment sequence. Trial Registration: The trial was registered with the University Hospital Medical Information Network (UMIN) Center under the identifier UMIN000015529 on November 1, 2014
- 14 August 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (8)
Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study
Background: Docetaxel (DTX) is commonly employed in patients with castration‐resistant prostate cancer (CRPC) following failure of androgen receptor signaling inhibitors (ARSIs). However, the impact of prior ARSI treatment on the efficacy of subsequent DTX therapy remains unclear. This study aimed to compare oncological outcomes between enzalutamide (ENZ)–DTX and abiraterone acetate plus prednisolone (ABI)–DTX sequential treatment strategies in patients with CRPC. Methods: The ENABLE study for PCa was an investigator‐initiated, multicenter, randomized controlled trial conducted in Japan to compare ENZ and ABI. This subanalysis evaluated the efficacy of subsequent DTX therapy in patients who had received either ENZ or ABI. Results: Between February 2015 and July 2019, 203 patients were enrolled, of whom 184 were randomized to receive ENZ or ABI (92 per arm). Among them, 20 and 21 patients subsequently initiated DTX therapy following ENZ and ABI, respectively. Median prostate cancer‐specific survival (PCSS) in the ENZ–DTX and ABI–DTX groups was 22.7 and 32.1 months, respectively ( p = 0.1724). Median PCSS from the initiation of DTX was 16.1 months in the ENZ–DTX group and 25.3 months in the ABI–DTX group ( p = 0.0966). In the overall cohort ( n = 41), patients who received additional ARSIs after ARSI–DTX therapy had significantly longer PCSS from the initiation of DTX compared with those who did not (median 21.6 vs. 13.8 months, p = 0.0157). Conclusions: ENZ–DTX and ABI–DTX sequential therapies demonstrated comparable survival outcomes in patients with CRPC. Notably, the administration of additional ARSIs following ARSI–DTX therapy may confer a survival benefit, suggesting a potential role for continued ARSI use in this treatment sequence. Trial Registration: The trial was registered with the University Hospital Medical Information Network (UMIN) Center under the identifier UMIN000015529 on November 1, 2014
- Open Access
- 9 August 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (5)
Penile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report
Introduction: Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation: The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The patient received luteinizing hormone‐releasing hormone agonist monotherapy. The patient developed castration‐resistant prostate cancer and received androgen receptor signal inhibitor therapy and chemotherapy. As the disease progressed, a mass formed on his penis; biopsy revealed prostate cancer penile metastasis. The patient died 5 months later. Conclusion: Penile metastasis is rare and typically observed in advanced prostate cancer stages. Awareness may aid in early recognition, guide palliative management, and support patient counseling.
- 9 August 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (5)
Open AccessPenile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report
Introduction: Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation: The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The patient received luteinizing hormone‐releasing hormone agonist monotherapy. The patient developed castration‐resistant prostate cancer and received androgen receptor signal inhibitor therapy and chemotherapy. As the disease progressed, a mass formed on his penis; biopsy revealed prostate cancer penile metastasis. The patient died 5 months later. Conclusion: Penile metastasis is rare and typically observed in advanced prostate cancer stages. Awareness may aid in early recognition, guide palliative management, and support patient counseling.
- Open Access
- 12 January 2026
- Published by MDPI AG in Preprints.org
Quartz Glass Fiber Sheet–Based Method for Enhancing Raman Scattering in Serum and Urine
Background/objectives: Diagnostic methods for minimally invasive disease are needed worldwide; Raman spectroscopy is a promising technology. In this study aiming to improve diagnostic technology using Raman spectroscopy, we evaluated a Raman spectroscopic substrate made of a quartz glass fiber sheet to obtain high sensitivity Raman spectra with a high signal-to-noise ratio. Methods: We investigated methods to amplify the intensity of Raman scattered light from humoral biological samples such as serum and urine. We evaluated two methodologies: 1) the needle method (NM) [for capturing Raman spectra by irradiating a droplet of liquid sample at the tip of a fine stainless-steel needle with a laser]; and 2) the quartz sheet method (QSM) [a quartz glass fiber sheet is saturated with a liquid sample, and the sheet surface is irradiated with a laser to obtain Raman spectra]. The Raman spectra of sodium benzoate, sodium sulfate, human serum, and human urine were recorded. Results: The samples crystallized and became concentrated in the quartz glass fiber sheet, allowing Raman spectra with highly intense scattered light to be recorded even from low-concentration samples. The QSM produced scattered light intensity ~7.3 and ~7.8 times higher for serum and urine, respectively, than the NM, which obtains spectra while the sample is still in liquid form. Conclusions: Our QSM enables quick and convenient acquisition of Raman spectra from samples using a very low-cost quartz glass fiber sheet and a standard Raman microscope. The QSM may be useful for obtaining Raman spectra from liquid biological samples with low analyte concentrations.
- 12 January 2026
- Published by MDPI AG in Preprints.org
Open AccessQuartz Glass Fiber Sheet–Based Method for Enhancing Raman Scattering in Serum and Urine
Background/objectives: Diagnostic methods for minimally invasive disease are needed worldwide; Raman spectroscopy is a promising technology. In this study aiming to improve diagnostic technology using Raman spectroscopy, we evaluated a Raman spectroscopic substrate made of a quartz glass fiber sheet to obtain high sensitivity Raman spectra with a high signal-to-noise ratio. Methods: We investigated methods to amplify the intensity of Raman scattered light from humoral biological samples such as serum and urine. We evaluated two methodologies: 1) the needle method (NM) [for capturing Raman spectra by irradiating a droplet of liquid sample at the tip of a fine stainless-steel needle with a laser]; and 2) the quartz sheet method (QSM) [a quartz glass fiber sheet is saturated with a liquid sample, and the sheet surface is irradiated with a laser to obtain Raman spectra]. The Raman spectra of sodium benzoate, sodium sulfate, human serum, and human urine were recorded. Results: The samples crystallized and became concentrated in the quartz glass fiber sheet, allowing Raman spectra with highly intense scattered light to be recorded even from low-concentration samples. The QSM produced scattered light intensity ~7.3 and ~7.8 times higher for serum and urine, respectively, than the NM, which obtains spectra while the sample is still in liquid form. Conclusions: Our QSM enables quick and convenient acquisition of Raman spectra from samples using a very low-cost quartz glass fiber sheet and a standard Raman microscope. The QSM may be useful for obtaining Raman spectra from liquid biological samples with low analyte concentrations.
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1) , 8111761
Neutropenia in Patients With Castration‐Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim
Background and Aims: Cabazitaxel has demonstrated survival benefits in patients with metastatic castration‐resistant prostate cancer (CRPC). However, Japanese patients are reported to experience higher rates of hematologic toxicity compared to their Caucasian counterparts. Although primary prophylaxis with pegfilgrastim is now routinely used in clinical practice, febrile neutropenia (FN) may still occur. In this study, we aimed to evaluate the real‐world safety of cabazitaxel with universal pegfilgrastim prophylaxis in Japanese patients with CRPC, particularly focusing on FN during the first treatment cycle. Methods: We retrospectively evaluated 86 patients with CRPC who received cabazitaxel at Showa Medical University–affiliated hospitals between 2015 and 2021. Cabazitaxel was administered every 3‐4 weeks at doses determined by the treating physicians, generally 20–25 mg/m 2 , with daily oral prednisolone. Pegfilgrastim was administered to all patients at least 24 h after cabazitaxel. Univariate analyses were performed to identify baseline factors associated with FN occurring during the first cycle of cabazitaxel. Exploratory logistic regression analysis was additionally performed for FN occurring during the entire treatment course. Results: Among the 86 patients, FN occurred in 12 patients (14.0%) during the entire treatment course, including 8 events (9.3%) during the first cycle. In univariate analyses, the only factor significantly associated with first‐cycle FN was a longer interval from CRPC diagnosis to cabazitaxel initiation (median, 1194.5 vs. 689 days, p = 0.0094). A similar tendency was observed when FN occurrence during the entire treatment course was analyzed. In exploratory logistic regression analysis for FN during the entire treatment course, the same factor showed a consistent trend toward association with FN development. Conclusion: Despite universal pegfilgrastim prophylaxis, approximately 10% of Japanese patients developed FN during the first cycle of cabazitaxel therapy. A longer interval from CRPC diagnosis to cabazitaxel initiation showed a consistent trend toward association with FN risk in Japanese patients across analyses. These findings provide real‐world safety data and highlight the importance of careful hematologic monitoring, particularly in patients treated later in the CRPC disease course.
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1) , 8111761
Open AccessNeutropenia in Patients With Castration‐Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim
Background and Aims: Cabazitaxel has demonstrated survival benefits in patients with metastatic castration‐resistant prostate cancer (CRPC). However, Japanese patients are reported to experience higher rates of hematologic toxicity compared to their Caucasian counterparts. Although primary prophylaxis with pegfilgrastim is now routinely used in clinical practice, febrile neutropenia (FN) may still occur. In this study, we aimed to evaluate the real‐world safety of cabazitaxel with universal pegfilgrastim prophylaxis in Japanese patients with CRPC, particularly focusing on FN during the first treatment cycle. Methods: We retrospectively evaluated 86 patients with CRPC who received cabazitaxel at Showa Medical University–affiliated hospitals between 2015 and 2021. Cabazitaxel was administered every 3‐4 weeks at doses determined by the treating physicians, generally 20–25 mg/m 2 , with daily oral prednisolone. Pegfilgrastim was administered to all patients at least 24 h after cabazitaxel. Univariate analyses were performed to identify baseline factors associated with FN occurring during the first cycle of cabazitaxel. Exploratory logistic regression analysis was additionally performed for FN occurring during the entire treatment course. Results: Among the 86 patients, FN occurred in 12 patients (14.0%) during the entire treatment course, including 8 events (9.3%) during the first cycle. In univariate analyses, the only factor significantly associated with first‐cycle FN was a longer interval from CRPC diagnosis to cabazitaxel initiation (median, 1194.5 vs. 689 days, p = 0.0094). A similar tendency was observed when FN occurrence during the entire treatment course was analyzed. In exploratory logistic regression analysis for FN during the entire treatment course, the same factor showed a consistent trend toward association with FN development. Conclusion: Despite universal pegfilgrastim prophylaxis, approximately 10% of Japanese patients developed FN during the first cycle of cabazitaxel therapy. A longer interval from CRPC diagnosis to cabazitaxel initiation showed a consistent trend toward association with FN risk in Japanese patients across analyses. These findings provide real‐world safety data and highlight the importance of careful hematologic monitoring, particularly in patients treated later in the CRPC disease course.
- Open Access
- 9 November 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 269, 117242
Development of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin
- 9 November 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 269, 117242
Open AccessDevelopment of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin
- Open Access
- 11 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 567
Predictive Factors and Clinical Impact of Radioactive Seed Migration After Prostate Brachytherapy: A Retrospective Study
Radioactive seed migration after low-dose-rate brachytherapy (LDR-BT) for prostate cancer is a known phenomenon; however, its clinical impact remains unclear. We retrospectively analyzed 611 patients treated with LDR-BT using loose iodine-125 seeds. Post-treatment imaging was used to assess seed migration. Treatment efficacy was evaluated using post-plan dosimetry (V100 and D90) and biochemical recurrence-free survival (bRFS). Seed migration was observed in 150 patients (24.5%) within 1–3 months post-treatment, involving a total of 210 seeds. Migration sites included lungs, vasculature, and seminal vesicles. Hematogenous migration was significantly associated with higher seed counts. Seminal vesicle migration was linked to increased needle usage and absence of neoadjuvant hormone therapy. No significant differences were observed in V100, D90, or bRFS between patients with or without seed migration. However, migration of ≥3 seeds correlated with significantly lower V100 and with a trend toward decreased bRFS. Limited seed migration appears to have minimal clinical impact. However, ≥3 migrated seeds may reduce dosimetric quality and affect treatment efficacy. Risk factors include larger prostate volume as well as higher seed and needle counts. Improved planning and using linked seeds may reduce migration and improve outcomes in LDR-BT for prostate cancer.
- 11 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 567
Open AccessPredictive Factors and Clinical Impact of Radioactive Seed Migration After Prostate Brachytherapy: A Retrospective Study
Radioactive seed migration after low-dose-rate brachytherapy (LDR-BT) for prostate cancer is a known phenomenon; however, its clinical impact remains unclear. We retrospectively analyzed 611 patients treated with LDR-BT using loose iodine-125 seeds. Post-treatment imaging was used to assess seed migration. Treatment efficacy was evaluated using post-plan dosimetry (V100 and D90) and biochemical recurrence-free survival (bRFS). Seed migration was observed in 150 patients (24.5%) within 1–3 months post-treatment, involving a total of 210 seeds. Migration sites included lungs, vasculature, and seminal vesicles. Hematogenous migration was significantly associated with higher seed counts. Seminal vesicle migration was linked to increased needle usage and absence of neoadjuvant hormone therapy. No significant differences were observed in V100, D90, or bRFS between patients with or without seed migration. However, migration of ≥3 seeds correlated with significantly lower V100 and with a trend toward decreased bRFS. Limited seed migration appears to have minimal clinical impact. However, ≥3 migrated seeds may reduce dosimetric quality and affect treatment efficacy. Risk factors include larger prostate volume as well as higher seed and needle counts. Improved planning and using linked seeds may reduce migration and improve outcomes in LDR-BT for prostate cancer.
- Open Access
- 16 January 2025
- Published by Science Publishing Group in International Journal of Clinical Urology
- Vol. 9 (1) , 13-19
Short-Term Quality of Life Outcomes: A Comparative Analysis of Thulium Laser Vaporization (ThuVap) vs. Transurethral Resection of the Prostate (TURP)
Objective: This study aimed to compare short-term quality of life (QOL) outcomes and perioperative parameters between transurethral resection of the prostate (TURP) and thulium laser vaporization of the prostate (ThuVap) in patients with benign prostatic hyperplasia (BPH). Materials and Methods: A retrospective analysis was conducted on 106 patients with BPH who underwent either TURP (n = 58) or ThuVap (n = 48) at our institution between April 2021 and August 2024. Preoperative and postoperative evaluations included the International Prostate Symptom Score (I-PSS), Overactive Bladder Symptom Score (OABSS), QOL index, and uroflowmetry. Perioperative outcomes, including operative time, catheterization duration, and hemoglobin (Hb) reduction, were also analyzed. Results: Both TURP and ThuVap showed sustained improvements in I-PSS, OABSS, and QOL index during the 3-month follow-up period, with no significant differences between the groups. ThuVap demonstrated a significantly lower rate of Hb reduction on the first postoperative day compared to TURP (5.9% vs. 8.5%, P < 0.05), likely due to reduced intraoperative bleeding. Although ThuVap had a shorter mean operative time (82.3 vs. 99.3 minutes), this difference was not statistically significant (P = 0.1). Discussion: The findings indicate that both TURP and ThuVap effectively improve postoperative QOL. ThuVap's reduced bleeding may provide advantages in patients with higher cardiovascular or bleeding risks. However, variations in operative time between studies may be influenced by factors such as surgeons' experience and institutional protocols. Conclusion: Both TURP and ThuVap are effective surgical options for improving QOL in BPH patients. However, surgical efficiency and outcomes may be influenced by the surgeon's expertise and the preoperative condition of the patients. ThuVap offers additional benefits of reduced intraoperative bleeding, which may support its use in selected cases.
- 16 January 2025
- Published by Science Publishing Group in International Journal of Clinical Urology
- Vol. 9 (1) , 13-19
Open AccessShort-Term Quality of Life Outcomes: A Comparative Analysis of Thulium Laser Vaporization (ThuVap) vs. Transurethral Resection of the Prostate (TURP)
Objective: This study aimed to compare short-term quality of life (QOL) outcomes and perioperative parameters between transurethral resection of the prostate (TURP) and thulium laser vaporization of the prostate (ThuVap) in patients with benign prostatic hyperplasia (BPH). Materials and Methods: A retrospective analysis was conducted on 106 patients with BPH who underwent either TURP (n = 58) or ThuVap (n = 48) at our institution between April 2021 and August 2024. Preoperative and postoperative evaluations included the International Prostate Symptom Score (I-PSS), Overactive Bladder Symptom Score (OABSS), QOL index, and uroflowmetry. Perioperative outcomes, including operative time, catheterization duration, and hemoglobin (Hb) reduction, were also analyzed. Results: Both TURP and ThuVap showed sustained improvements in I-PSS, OABSS, and QOL index during the 3-month follow-up period, with no significant differences between the groups. ThuVap demonstrated a significantly lower rate of Hb reduction on the first postoperative day compared to TURP (5.9% vs. 8.5%, P < 0.05), likely due to reduced intraoperative bleeding. Although ThuVap had a shorter mean operative time (82.3 vs. 99.3 minutes), this difference was not statistically significant (P = 0.1). Discussion: The findings indicate that both TURP and ThuVap effectively improve postoperative QOL. ThuVap's reduced bleeding may provide advantages in patients with higher cardiovascular or bleeding risks. However, variations in operative time between studies may be influenced by factors such as surgeons' experience and institutional protocols. Conclusion: Both TURP and ThuVap are effective surgical options for improving QOL in BPH patients. However, surgical efficiency and outcomes may be influenced by the surgeon's expertise and the preoperative condition of the patients. ThuVap offers additional benefits of reduced intraoperative bleeding, which may support its use in selected cases.
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (2) , 149-152
A case of acute myocardial infarction due to Kounis syndrome after brachytherapy for prostate cancer
Major systemic complications during and immediately after brachytherapy are rare. Herein, we described a case of acute myocardial infarction due to Kounis syndrome after low-dose-rate brachytherapy in a 70-year-old man with a banana allergy. Following low-dose-rate brachytherapy under general...
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 17 (2) , 149-152
Open AccessA case of acute myocardial infarction due to Kounis syndrome after brachytherapy for prostate cancer
Major systemic complications during and immediately after brachytherapy are rare. Herein, we described a case of acute myocardial infarction due to Kounis syndrome after low-dose-rate brachytherapy in a 70-year-old man with a banana allergy. Following low-dose-rate brachytherapy under general...
- Open Access
- 26 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.
- 26 December 2024
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 95 (1) , 1-10
Open AccessVariations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.